






## Correction: Brolucizumab—early real-world experience: BREW study

Ashish Sharma  · Nilesh Kumar  · Nikulaa Parachuri · Srinivas R. Satta · Giulia Corradetti  · Jeffrey Heier · Adam T. Chin  · David Boyer · Pouya Dayani · Sruthi Arepalli · Peter Kaiser 

Published online: 15 December 2020  
© The Royal College of Ophthalmologists 2020

Correction to: *Eye*

<https://doi.org/10.1038/s41433-020-1111-x>

Since online publication of this article, the authors became aware of two errors in the text of the manuscript:

1. Page 1 Paragraph 1, an incorrect approval date was inserted. The correct sentence is provided below:

Brolucizumab (Beovu, Novartis, Basel, Switzerland) is the newest anti-vascular endothelial growth factor (anti-VEGF) drug. It was approved for the treatment of neovascular age-related macular

degeneration (nAMD) by the US-FDA on October 7, 2019, followed by the European Commission's approval for use in the European Union on February 13, 2020.

2. Page 2 Paragraph 1, an incorrect percentage was provided. The correct sentence is provided below:

Pigment epithelial detachment (PED) was present in 31 eyes (73.8%) at baseline and resolved in 2 eyes (6.4%), was reduced in 13 eyes (41.9%), and did not show any change in 16 eyes (51.6%) (Fig. 1).

The authors apologise for any inconvenience caused.